---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105185"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:01:45.528510+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance

## Summary
- Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.
- EPS $3.40 (+21% reported, +15% comparable); operating margin 32.1%, +100 bps reported.
- Raises FY2025 revenue guidance to $4,270-$4,300M (midpoint +$43M) and EPS guidance to $12.81-$13.01 (midpoint +$0.33).
- Over 1,700 IDEXX inVue Dx placements in Q3; strong capital instrument revenue growth of 74% reported.
- Updated FY2025 organic revenue growth outlook 8.8%-9.5%; comparable margin expansion guidance raised to 80-100 bps.

## SEC filing metadata
- accession: 0001104659-25-105185
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/0001104659-25-105185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/tm2530045d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105185
- JSON: https://secwatch.observer/filing/0001104659-25-105185.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.